

An Open Letter to the Community About the Transition of CRYSVITA® (burosumab-twza) Injection to Kyowa Kirin

January 2023

With the new year often comes new beginnings. For nearly a decade, Kyowa Kirin and Ultragenyx Pharmaceutical Inc. have successfully partnered together to develop and make CRYSVITA® (burosumab-twza) injection available to appropriate patients around the world, with Ultragenyx focused on North America, Latin America and Turkey, and Kyowa Kirin on Europe, Asia and Australia.

In April we enter the next phase of our collaboration as Kyowa Kirin assumes primary commercial responsibilities for CRYSVITA in the U.S. and Canada, including responsibility for providing patient services. Understandably, this news may raise questions among those who rely on the current Ultragenyx UltraCare® program for access to treatment and support. Please know that as we continue to work together on transition plans, ensuring continued access to CRYSVITA remains a top priority.

Starting May 1, 2023, Kyowa Kirin Cares will provide personal and comprehensive support to CRYSVITA patients and caregivers from the time the prescription is written and throughout their treatment journey. Like UltraCare, the U.S. program will offer a familiar suite of services related to insurance and access, financial assistance, and treatment education, including:

- A dedicated Case Manager to help patients understand their financial options based on their insurance coverage,
- Financial services including a copay program for patients with commercial insurance and a Patient Assistance Program for patients without insurance, and
- Regular case manager check-ins to offer support, answer questions, and provide educational resources.

To remain eligible for support services, including certain financial assistance programs, patients and caregivers enrolled in the U.S. UltraCare program must opt-in to Kyowa Kirin Cares before May 1, 2023. Further instruction on how to opt-in using either print or digital options has been sent to current UltraCare members. If you do not receive this information by the end of February or have questions, please call 833-KK-CARES (833-552-2737). Further detail about the transition of Canadian services will be shared with patients in the coming months. To learn more about Kyowa Kirin, go to www.PatientTransitionKyowaKirin.com.

As we look ahead to the spring, we remain committed to doing all we can to ensure a smooth transition for everyone.

Sincerely,



Lauren Walrath, MBA
VP, Public Affairs & Advocacy
Kyowa Kirin North America



Jessica Riviere, MHS
VP, Head of Patient Advocacy & Patient Engagement
Ultragenyx Pharmaceutical Inc.